Nasdaq

Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications

Data shows that INO-3107 induced new populations of T cells in the blood that traveled to airway tissue and were associated with clinical benefit as measured by reduced need for surgeries Dr. Matthew ...
Seeking Alpha

INOVIO Receives FDA Feedback that Data from Completed Phase 1/2 Trial of INO-3107 Can Be Used to Submit a BLA Under Accelerated Approval Program

Previously planned Phase 3 trial no longer required to support Biological License Application (BLA) submission If approved, INO-3107 could potentially revolutionize treatment options for patients with ...